NCT01189019View on ClinicalTrials.gov

HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Wet Macular DegenerationMacular DegenerationRetinal Pigment Epithelial Detachment
Interventions
DRUG

ranibizumab

2mg intravitreal injection monthly

DRUG

ranibizumab

2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT

Trial Locations (3)

37203

Tennessee Retina, Nashville

40509

Retina Associates of Kentucky, Lexington

94115

Pacific Eye Associates, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Anne Fung MD

OTHER